Skip to main content

Advertisement

SpringerLink
Log in

Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Acute myeloid leukemia (AML) harboring Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutation is associated with shorter remission and higher relapse risk. Several FLT3 inhibitors have been used in clinical trials, but their efficacy in extramedullary disease remains unclear. In the present case, a 56-year-old man was diagnosed with FLT3-ITD mutated AML. Due to bone marrow relapse during consolidation therapy, he underwent salvage therapy and a myeloablative conditioning regimen, followed by peripheral blood stem cell transplantation (PBSCT) from a HLA-matched related donor. Acute graft-versus-host disease (GVHD) did not develop, and complete donor chimerism was confirmed on days 27 and 96 after PBSCT. On day 180, he experienced extensive chronic GVHD and had several subcutaneous tumors in his body, which were diagnosed as myeloid sarcoma by pathological examination. We considered this to be a case of isolated extramedullary relapse, as his bone marrow had maintained complete donor chimerism. Treatment with etoposide and ranimustine produced no effect, and tumor progression continued. We started administration of gilteritinib, a FLT3/AXL inhibitor, after identifying the FLT3-ITD mutation in the tumor. Subsequently, there has been a remarkable regression of the tumors. Gilteritinib can be effective in isolated extramedullary relapse after allogeneic stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yuda S, Fuji S, Onishi A, Tanaka T, Inatomo Y, Kurosawa S, et al. Extramedullary relapse of acute myelogenous leukemia after allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1152–7.

    Article  Google Scholar 

  2. Ando T, Mitani N, Matusi K, Yamashita K, Nomiyama J, Tsuru M, et al. Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t (8;21) and CD56-positivity. Int J Hematol. 2009;90:374–7.

    Article  Google Scholar 

  3. Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30:333–9.

    Article  Google Scholar 

  4. Lee JH, Choi SJ, Seol M, Lee YS, Ryu SG, Park CJ, et al. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica. 2005;90:1380–8.

    PubMed  Google Scholar 

  5. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioqlu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–28.

    Article  CAS  Google Scholar 

  6. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  7. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori A, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735–41.

    Article  Google Scholar 

  8. Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur J Haemal. 2017;98:330–6.

    Article  Google Scholar 

  9. Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, et al. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019;110:665–74.

    Article  CAS  Google Scholar 

  10. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutation in acute myeloid leukemia. Blood. 1999;93:3074–80.

    CAS  PubMed  Google Scholar 

  11. Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, et al. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. Leuk Lymphoma. 2016;57:2541–7.

    Article  CAS  Google Scholar 

  12. Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5:96–102.

    Article  CAS  Google Scholar 

  13. Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant. 2012;18:1800–7.

    Article  Google Scholar 

  14. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, et al. Extramedullary relapse of acute myeloid leukemia following allogeneic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2013;98:179–84.

    Article  Google Scholar 

  15. Yoshihara S, Ikegame K, Kaida K, Taniguchi K, Kato R, Inoue T, et al. Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome. Bone Marrow Transplant. 2012;47:669–76.

    Article  CAS  Google Scholar 

  16. Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109:2264–5.

    Article  Google Scholar 

  17. Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med. 2010;220:121–6.

    Article  CAS  Google Scholar 

  18. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Bloomfield CD, Thiede C, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.

    Article  CAS  Google Scholar 

  19. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed/refractory acute myeloid leukemia: a multicenter, first-in-human, open-label, phase 1/2 study. Lancet Oncol. 2017;18:1061–75.

    Article  CAS  Google Scholar 

  20. Gorcea CM, Burthem J, Tholouli E. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Fut Oncol. 2018;14:1995–2004.

    Article  CAS  Google Scholar 

  21. Perl AE, Martinelli G, Cortes JE, Naubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728–40.

    Article  CAS  Google Scholar 

  22. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichier S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567–71.

    Article  CAS  Google Scholar 

  23. Sora F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Leurenti L, et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. Leuk Res. 2011;35:422–3.

    Article  Google Scholar 

  24. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17:1874–7.

    Article  CAS  Google Scholar 

  25. Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol. 2015;94:1899–905.

    Article  CAS  Google Scholar 

  26. Safaian NN, Czibere A, Bruns I, Fenk R, Reinnecke P, Dienst A, et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2009;33:348–50.

    Article  CAS  Google Scholar 

  27. Lee SH, Paietta E, Racevskis J, Wiernik PH. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol. 2009;84:701–2.

    Article  Google Scholar 

  28. Takahashi N, Kawakami T, Sato H, Onoda T, Kanno M, Mitsui T, et al. Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD. Rinsho Ketsueki. 2012;53:1932–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama-chou, Kure, Hiroshima, 737-0023, Japan

    Michiko Kida, Miki Kido, Ren Chishaki & Takuo Ito

  2. Department of Hematology, National Hospital Organization, Hiroshima-Nishi Medical Center, Otake, Japan

    Yoshiaki Kuroda

  3. Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan

    Kazuya Kuraoka

Authors
  1. Michiko Kida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miki Kido
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ren Chishaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuya Kuraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuo Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michiko Kida.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kida, M., Kuroda, Y., Kido, M. et al. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Int J Hematol 112, 243–248 (2020). https://doi.org/10.1007/s12185-020-02855-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02855-4

Keywords

Search

Navigation